tisagenlecleucel + CD22 CAR-T

tisagenlecleucel + CD22 CAR-T is an investigational sequential CAR T-cell regimen in which patients first receive commercial tisagenlecleucel, a CD19-directed autologous CAR T-cell product, followed 28–42 days later by an autologous CD22-directed CAR T-cell infusion to provide dual CD19/CD22 antigen targeting in relapsed or refractory CD19/CD22-positive B‑cell malignancies.[1][2][7] The strategy is intended to enhance depth and durability of B-cell leukemia/lymphoma responses and mitigate CD19 antigen-loss relapse seen after CD19-only CAR T therapy by adding a CD22 CAR T product (CD22CART) once initial disease debulking and in vivo expansion of tisagenlecleucel have occurred.[1][2] Early phase trials in children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia and other B‑cell malignancies focus on defining the safety, feasibility, maximum tolerated dose, and recommended phase 2 dose of CD22 CAR T cells given after tisagenlecleucel, as well as on characterizing serial dual-antigen targeting and sustained B‑cell aplasia as measures of ongoing CAR T activity.[1][2]

Other names

tisagenlecleucel plus CD22 CAR-Ttisagenlecleucel followed by CD22 CAR-Tcommercial tisagenlecleucel plus CD22CART